Evaluation of Aminoglutethimide in Stage D Prostate Cancer: An Assessment of Efficacy ani Toxicity in Patients With Tumors Refractory to Hormonal Therapy

Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment

“…Aminoglutethmide was shown to decrease adrenal androgen levels similar to those achieved after bilateral adrenalectomy 11, 12. Aminoglutethmide was co-administered initially with cortisone 13 and then with hydrocortisone 14.…”

Treatment of Hormone-Refractory Prostate Carcinoma

“…The results of the trials using different drugs are indicated in table 1. Aminoglutéthimide [18][19][20][21][22] and kétoconazole [23,24] are no longer used because of side effects and the need for hydrocortisone supplementation. As reported by Mahler et al [24], liarozole is better tolerated and were results promising [24].…”

“…The molecular mecha nism involved in this phenomenon remains unknown, but androgen receptor mutation occurring during tumor pro gression could play a role in the agonist effect of antian drogens [8], Clinical improvement and/or biological response (de crease of serum PSA level >50% from baseline) after withdrawal of antiandrogens were evaluated in several studies of HRPC patients while on maximal androgen deprivation [9][10][11][12], In these series, responses were re ported in 15-42% (biological response) and 25% (clinical improvement) of HRPC patients, after withdrawal of flutamide. The response occurred in most cases within 6 weeks and the mean duration of response was [3][4] Hormone-Refractory PCa EurUrol 1996;30(suppl l):32-37 Aminoglutéthimide + hydrocortisone [18][19][20][21][22] Kétoconazole [23,24] 395 (6 trials)…”

Aminoglutethimide for Advanced Prostatic Cancer Resistant to Conventional Hormonal Therapy

“…Skeletal surveys, hone scans and ultrasound measurement of the residual urine and flowmetry were repeated at 4-month intervals. [ 15] have reported lack of efficacy of AG + HC on prostatic cancer resistant to stan dard hormonal therapy. Although there are differences between patient material and treatments these contro versies in response rate are difficult to explain.…”

“…Although there are differences between patient material and treatments these contro versies in response rate are difficult to explain. One pos sibility is that the pharmacokinetics of AG are variable [15].…”